Head Of U.S. National Institutes Of Health Warns Court Ban On Funding For Embryonic Stem Cell Research Could Trigger Flight Of Best Scientists To Rival Centers Abroad
This article was originally published in PharmAsia News
Executive Summary
BEIJING - As lawyers for the United States Department of Justice and for those seeking to halt all federal funding for embryonic stem cell research prepare for a new round of battle in a U.S. Court of Appeals, the head of the National Institutes of Health is warning that a funding freeze could trigger an exodus of the best embryonic stem cell scientists to rival centers abroad
You may also be interested in...
U.S.-based NeoStem Signs Twin Agreements To Provide Stem Cell Treatments To Chinese Hospitals
BEIJING - The New York-headquartered biopharmaceutical firm NeoStem Inc has signed twin agreements to provide a leading-edge stem cell-based orthopedic therapy to two Chinese hospitals
U.S.-based NeoStem Signs Twin Agreements To Provide Stem Cell Treatments To Chinese Hospitals
BEIJING - The New York-headquartered biopharmaceutical firm NeoStem Inc has signed twin agreements to provide a leading-edge stem cell-based orthopedic therapy to two Chinese hospitals
U.S. Court Ban On Federal Funding For Embryonic Stem Cell Research Would Help China In Race To Lead The Field
BEIJING - If a court battle now being waged in the American federal judiciary over embryonic stem cell research ends with a new ban on U.S. government funding for these studies, the freeze would give China a boost in its race to become a dominant power in this field, according to a scholar who tracks stem cell research on both sides of the Pacific